The global specialty generics market was worth US$ 57.4 Bn in 2021 and is set to expand 2.1X over the next ten years.
The specialty generics market is expected to reach US$ 130.5 Bn by end of 2032 at a CAGR of 7.7%.
The growing burden of chronic and infectious disease, rising awareness regarding high-level therapeutics and sustainable production methods, and the adoption of complex generics, are some of the key trends in this market.
North America has the highest market share of about 36.7% by value in 2021 in the global specialty generics market.
India accounts for about 45.8% of the market share in 2021 in the South Asia specialty generics market and is projected to grow with a CAGR of 4.9% in the forecast period.
India, the U.S., China, the U.K, and Germany are the top five countries, which are expected to drive demand in the specialty generics market.
Teva Pharmaceuticals Industries, Akorn, Inc., Mylan N.V., Mallinckrodt, Sandoz International GmbH, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, Apotex Corp., Endo International plc are some of the key players in the specialty generics industry.
China accounted for 33.3% market share by value in 2021 within the region of East Asia. The specialty generics market in China is expected to grow at a 4.5% CAGR value during the forecast period.
Japan displays a share of around 43.0% in 2021 within East Asia and is set to present a lucrative CAGR growth rate of 5.8% during the forecast period.
Specialty Generics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
